Inhibrx Biosciences
(NASDAQ) INBX
Inhibrx Biosciences Financials at a Glance
Market Cap
$927.98M
Revenue (TTM)
$1.30M
Net Income (TTM)
$140.06M
EPS (TTM)
$-9.04
P/E Ratio
-7.02
Dividend
$0.00
Beta (Volatility)
1.04 (Average)
Dividend
$0.00
Beta (Volatility)
1.04 (Average)
Price
$63.59
Volume
10,753
Open
$64.48
Price
$63.59
Volume
10,753
Open
$64.48
Previous Close
$63.59
Daily Range
$63.04 - $65.59
52-Week Range
$10.80 - $94.56
Dividend
$0.00
Beta (Volatility)
1.04 (Average)
Price
$63.59
Volume
10,753
Open
$64.48
Previous Close
$63.59
Daily Range
$63.04 - $65.59
52-Week Range
$10.80 - $94.56
INBX News
INBX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Inhibrx Biosciences
Industry
Biotechnology
Sector
Health CareEmployees
110
CEO
Mark Paul Lappe
Website
www.inhibrx.comHeadquarters
La Jolla, CA 92037, US
INBX Financials
Key Financial Metrics (TTM)
Gross Margin
-91%
Operating Margin
-104%
Net Income Margin
-108%
Return on Equity
-198%
Return on Capital
-1%
Return on Assets
-96%
Earnings Yield
-14.25%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$927.98M
Shares Outstanding
14.61M
Volume
10.75K
Short Interest
0.00%
Avg. Volume
197.60K
Financials (TTM)
Gross Profit
$1.18M
Operating Income
$135.03M
EBITDA
$132.54M
Operating Cash Flow
$129.79M
Capital Expenditure
$31.00K
Free Cash Flow
$129.82M
Cash & ST Invst.
$124.22M
Total Debt
$107.01M
Inhibrx Biosciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$564.00K
+4.2%
Gross Margin
0.00%
N/A
Market Cap
$927.98M
N/A
Market Cap/Employee
$5.95M
N/A
Employees
156
N/A
Net Income
$32.83M
+31.4%
EBITDA
$36.25M
+23.2%
Quarterly Fundamentals
Net Cash
$17.21M
-88.1%
Accounts Receivable
$177.00K
-57.9%
Inventory
$0.00
N/A
Long Term Debt
$104.69M
+1522.3%
Short Term Debt
$2.33M
+45.8%
Return on Assets
-95.62%
N/A
Return on Invested Capital
-1.20%
N/A
Free Cash Flow
$30.12M
+31.1%
Operating Cash Flow
$30.12M
+31.1%